Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Localised prostate cancer, high and very high risk, drawn from the whole corpus: 42 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
How long hormone therapy should last when abiraterone is added.
Whether PSMA PET-detected nodes should change treatment when the trials were staged conventionally.
Which men with high-risk disease are better served by surgery than radiotherapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 29 changes by month →When this page itself was last checked or edited.
Ten-year metastasis-free survival 78.
A milestone in how this cancer is treated.
Transdermal oestradiol suppressed testosterone as well as a luteinising hormone-releasing hormone agonist with no difference in time to first cardiovascular event (hazard ratio 1.
Per-patient sensitivity 0.
Event-free survival hazard ratio 0.